Bringing more to parenteral nutrition (PN)
As the US market leader in lipid injectable emulsions (ILEs),1 Fresenius Kabi offers more options, more choices, and more variety to nourish critically or chronically ill patients of any age—from hospital to home.
Innovative
PN products
Lipid source matters. Learn about Fresenius Kabi’s alternative lipid sources in PN.
Meet the
experts in PN
Tune in to expert discussions surrounding the world of PN, from drug shortages to patient case studies to transitioning patients home on PN.
At the forefront of PN
A tireless dedication to driving advancements in lifesaving medicines and technologies has led to many firsts in the field, like introducing the first lipid PN product for adults in more than 40 years, keeping Fresenius Kabi at the forefront of PN.*
2024
Developed Y-site drug compatibility and admixture stability reference guides for adult and pediatric patients
2023
Developed an admixture stability reference guide for pediatric patients
2023
A 100% soybean oil ILE came back to Fresenius Kabi
2022
The first 4-oil ILE product approved for pediatric patients, including term and preterm neonates
2018
Developed the only pediatric ILE product for PN-associated cholestasis (PNAC) in the US
2016
Brought the benefits of alternative lipid emulsions to market
2016
Pioneered the use of fish oil and omega-3s in PN products
2014
Developed the first and only 3-chamber bag for adult PN in the US
Stay tuned for more in PN
Future innovations in the works
*Portfolio data on file.
